 |
|
Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide
Hyeyeon Hong, Won-Mook Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Jonggi Choi
Clin Mol Hepatol. 2024;30(1):49-63. Published online 2023 Nov 20 DOI: https://doi.org/10.3350/cmh.2023.0328
|
|
Citations to this article as recorded by
 Letter: Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in patients with chronic hepatitis B: More questions than an answer – author’s reply
Hyeyeon Hong, Jonggi Choi
Clinical and Molecular Hepatology.2024; 30(2): 272. CrossRef Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer
Pin-Nan Cheng, Ming-Lung Yu
Clinical and Molecular Hepatology.2024; 30(2): 144. CrossRef Lipid safety of tenofovir alafenamide during 96-week treatment in treatment-naive chronic hepatitis B patients
Wenjuan Zhao, Yi Liu, Mengdi Zhang, Zixin Cui, Zhan Qu, Yiyang Li, Meijuan Wan, Wen Wang, Yunru Chen, Lei Shi, Jianzhou Li, Feng Ye
Frontiers in Medicine.2024;[Epub] CrossRef Reply to “Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in HBV patients”
Pin-Nan Cheng, Ming-Lung Yu
Clinical and Molecular Hepatology.2024;[Epub] CrossRef
|